Two medicines, side by side
Ivabradine vs digoxin
Ivabradine and digoxin are both labeled for heart failure. Drugs@FDA records approvals of ivabradine since 2015 and of digoxin since 1954. Pharmacies paid $0.761 per ivabradine HCl 5 mg tablet and $0.133 per digoxin 125 mcg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker and digoxin a cardiac glycoside.
Check it at the source: the ivabradine FDA label on DailyMed (effective November 10, 2025); the digoxin FDA label on DailyMed (effective December 5, 2024).
Highlights of the ivabradine record
Ivabradine (Corlanor) · label of November 10, 2025
Used for
From the label: indicationsINDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. […]
On the market
- Earliest approval on file
- April 15, 2015
- Generic labelers
- 11 labelers
- Pharmacy cost
- $0.761 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 2
Highlights of the digoxin record
Digoxin (Lanoxin) · label of December 5, 2024
Used for
From the label: indicationsLANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults LANOXIN is indicated for the treatment of mild to moderate heart failure in adults. […]
On the market
- Earliest approval on file
- November 16, 1954
- Generic labelers
- 26 labelers
- Pharmacy cost
- $0.133 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 4
Source: FDA drug labels via openFDA (Ivabradine label of November 10, 2025, Digoxin label of December 5, 2024); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do ivabradine and digoxin differ on the record?
In FDA's classes, ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker and digoxin a cardiac glycoside.
How each works, in its label's words: Ivabradine, “Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate.”; Digoxin, “This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells.”
Half-life, in each label's words: Ivabradine, “Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 …”; Digoxin, “In healthy volunteers with normal renal function, digoxin has a half-life of 1.5-2 days.”
Generics: ivabradine since 2021; digoxin since 1975 (Drugs@FDA).
| Ivabradine | Digoxin | |
|---|---|---|
| Labeled for | Heart failure | Heart failure, Atrial fibrillation |
| Pharmacologic class | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker | Cardiac Glycoside |
| How it works (label) | Corlanor blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. | All of digoxin’s actions are mediated through its effects on Na-K ATPase. This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into … |
| Half-life (label) | Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours. | In healthy volunteers with normal renal function, digoxin has a half-life of 1.5-2 days. |
| Earliest approval on file (Drugs@FDA) | April 15, 2015 | November 16, 1954 |
| First generic approved | December 30, 2021 | October 24, 1975 |
| Generic labelers (NDC) | 11 labelers | 26 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.761 per tablet (Ivabradine HCl 5 mg tablet) | $0.133 per tablet (Digoxin 125 mcg tablet) |
| 12-month price change | -75% | +20% |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | No current entry |
| Recalls recorded | 2 | 4 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,817 | 71,335 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Digoxin label, drug interactionsHyperpolarization-activated cyclic nucleotide-gated channel blocker; Ivabradine; Can increase the risk of bradycardia
Digoxin label, drug interactionsIvabradine Can increase the risk of bradycardia.
Source: FDA drug labels via openFDA
What next?
- Alternatives to ivabradine
- every medicine labeled for the same conditions